The Effect of Integrated Mobile Health-supported Heart Rhythm Management Around Electrical Cardioversion in Terms of Cancelling Unnecessary Scheduled ECV Appointments in Patients With Presumed Persistent Atrial Fibrillation (TeleConvert-AF)

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Despite a clear definition in the European Society of Cardiology (ESC) guidelines, the differentiation between paroxysmal (self-terminating) and persistent (nonself- terminating) atrial fibrillation (AF) remains challenging in clinical practice. Some patients with presumed persistent AF are planned for electrical cardioversion (ECV) but appear to have a paroxysmal pattern or present in sinus rhythm (SR) at the scheduled ECV appointment. This results in unnecessary visits or interventions for patients, and costs and burden for the hospitals and health insurances. Based on the feasibility of the TeleCheck-AF approach, which is an on-demand mobile health (mHealth) infrastructure incorporating app-based heart rate and rhythm monitoring to support remote AF management through teleconsultation, the investigators aim to extend this mHealth approach to the management of presumed persistent AF patients planned for ECV.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Presumed persistent AF

• Scheduled for ECV

• Age ≥18 years

• Smartphone possession

• Ability and willing to sign informed consent

• Ability and willing to use mobile phone app (FibriCheck)

Locations
Other Locations
Netherlands
Maastricht University Medical Center
RECRUITING
Maastricht
Viecuri Medical Center
RECRUITING
Venlo
Contact Information
Primary
Dominik Linz, dr.
dominik.linz@mumc.nl
043-3877098
Backup
Astrid Hermans, MSc
astrid.hermans@mumc.nl
043-3871613
Time Frame
Start Date: 2022-01-01
Estimated Completion Date: 2025-01-01
Participants
Target number of participants: 264
Treatments
TeleConvert-AF
Patients with presumed persistent AF, age ≥18 years, scheduled for ECV, and in possession of a smartphone will be included in this study from January 2022 to January 2025.
Related Therapeutic Areas
Sponsors
Leads: Maastricht University Medical Center

This content was sourced from clinicaltrials.gov